(Q43622978)

English

Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

0 references

0 references

author name string

A Yoshioka

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Shima

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

K Fukutake

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

J Takamatsu

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

A Shirahata

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Coganate FS Study Group

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

242-249

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00511.X

21 January 2018

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00511.X

21 January 2018

New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00511.X

21 January 2018

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00511.X

21 January 2018

Investigation of an outbreak of hepatitis A in Irish haemophilia A patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00511.X

21 January 2018

Clotting factor concentrates and immune function in haemophilic patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2001.00511.X

21 January 2018

Identifiers

10.1046/J.1365-2516.2001.00511.X

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43622978&oldid=2101946962"